GlassScriptPhysician profile
Richard C Cape
NPI 1386602159
$4,965.68
in general payments reported to CMS, 2019-2025
32 companies · $1,363 in 2025
The $1,363 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $354 · 2021: $373 · 2022: $390 · 2023: $725 · 2024: $931 · 2025: $1,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,994 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,993.81 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $824.65 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Allergan, INC. | $786.33 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $432.38 | 2022-2025 | Cequa |
| Bausch & Lomb Americas INC. | $370.68 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Harrow Eye, LLC | $250.36 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $247.75 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Glaukos Corporation | $239.55 | 2019-2025 | Idosetr |
| Alcon Vision LLC | $234.67 | 2019-2025 | Clareon, Hydrus Microstent |
| Rxsight INC | $201.93 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Omeros Corporation | $169.97 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $151.22 | 2021-2023 | Tecnis Iol |
| Amneal Pharmaceuticals LLC | $140.77 | 2022-2025 | Rytary, Crexont |
| Sight Sciences, INC. | $132.70 | 2020-2024 | Omni Surgical System |
| Rayner Intraocular Lenses Limited | $92.92 | 2022-2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Biotissue Holdings INC. | $71.99 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $70.18 | 2022-2025 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Novartis Pharmaceuticals Corporation | $69.59 | 2021-2023 | |
| Aerie Pharmaceuticals, INC. | $66.10 | 2019-2020 | |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $63.88 | 2024 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $56.94 | 2019 | |
| Eyepoint US, INC. | $42.24 | 2019 | |
| Ucb, INC. | $25.94 | 2025 | Rystiggo |
| Eyevance Pharmaceuticals LLC | $22.93 | 2022 | |
| Shire North American Group INC | $21.56 | 2019 | |
| Ocular Therapeutix, INC. | $20.86 | 2024 | Dextenza |
| Apellis Pharmaceuticals, INC. | $18.43 | 2024 | Syfovre |
| Dompe US, INC. | $17.68 | 2024 | Oxervate |
| Lundbeck LLC | $16.48 | 2022 | |
| Horizon Therapeutics Plc | $15.20 | 2023 | Tepezza |
| Adamas Pharmaceuticals, INC. | $14.74 | 2019 | |
| Iridex Corporation | $10.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Cape listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.